The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
My thinking is there must be some big contract win coming Novacyt's way from Yourgene's business, and LR has been rewarded. Clearly, Yourgene is the driving force of Novacyt's growth strategy, and who knows Yourgene better than anyone is LR and Joanne Mason. James Wakefield would not have appointed LR if there is not something big imminent, such as a big contract win.
HC , should Novacyt really be going after companies like GDR that are not profit making ? I think Novacyt should really be going for companies that have already products that are on market and making profit .
So since 2016 , Novacyt , under the leadership of Graham Mullis , have been talking about 'organic growth' . I just wonder where this company would be now if Graham Mullis was still CEO , and we hadn't had those 12 months of stagnation with David Allmond and another 12 months now of James McCarthy as CEO . Would we have had any better forward strategy and more acquisitions with GM ?
The current share price of Novacyt is 45p , but does this really reflect its total assets built over the years from acquisitions. Take a look at each acquisition and think how much is this company really worth ? Now , with more cash following DHSC case , amounting to possible total £130M , this would generate a few more big acquisitions . This would easily generate £100M+ revenue per year.
https://tracxn.com/d/acquisitions/acquisitions-by-novacyt/__7Y3NIyA4Onaifbi_buR8Zn16EDg3jGZUXPnWB7UUiyw
I was looking back at the history of Novacyt and its acquisition of primerdesign in 2016 .
https://www.businesswire.com/news/home/20160117005110/en/Novacyt-Announces-Proposed-Acquisition-of-Primer-Design-Ltd
We may all feel critical of James Wakefield and John McCarthy with how the SP has been run down and disintegrated share hold value , but you know this could be a master stroke strategy by JW and deliberately done for the court case . It will demonstrate to the judge how badly the company has been damaged by the actions of the DHSC . Let's hope so.
It could well be we get a RNS 1-2 weeks coming up to the court case and both Novacyt and DHSC come to some settlement . But , that settlement would be at Novacyt's favour. Possibly the DHSC drop the £135M dispute and agree to half of what Novacyt are asking which is ~ £40M .
I think Novacyt will get between £40 - 81m from this DHSC case , resulting in cash balance of £80M - £130+M in the bank for acquisitions / mergers .
Valju , what i predict is this . I see Novacyt receiving all their money from the DHSC dispute with interest and their counterclaim . I believe JW is the one who is dictating things at Novacyt and his strategy is to take this to court , show the judge the impact it has had on the SP by the DHSC dispute and how it could threaten the livelihood of 250 + employees at Novocyt . This is why we do not get any RNS hyping the share price . I feel the SP will shoot up to £5 + once the DHSC case is won in court , Novacyt acquire another acquisition within 4-6 weeks of court case , directors also buying in . I think Novacyt will take this to court unless the DHSC agree to pay up . Simple .
Yes , i am fu*ked if Novacyt lose the case .
Let's have a vote , who do we want as CEO ?
1. Graham Mullis - he knows the molecular diagnostic industry . Will have contacts which will lead to acquisitions and mergers. He did say in October 2020 that his ambition was to make Novacyt a mid cap company.
2. Lyn Rees - He knows Yourgene inside out , his plans are very ambitious for Yourgene . His presentations come across dynamic.
3. Someone new from a blue chip company with a good background of contacts in molecular diagnostics. Someone who wants to step upto to a CEO position .
4. Stick with James McCarthy
I wouldn't have thought Yourgene were recruiting if there was any inkling of Novacyt losing the DHSC case. It's looks like full throttle with recruiting at Yourgene. This also demonstrates that Yourgene will be the main business of Novacyt , which could well mean LR becoming the new CEO.
Looks like our R&D head , Dr Joanne Mason, likes Yourgene HR .... it's interesting how many likes she clicked onto everyday..... hope she is actually doing some R&D . Looks to me she is hyperactive on LinkedIn.
https://www.linkedin.com/posts/richard-miller-yourgene_its-always-great-to-be-back-at-a-familiar-activity-7176106219797934080-kIoC?utm_source=share&utm_medium=member_android
So how would James McCarthy's performance be compared to David Allmond . Both men have maintained the same strategy of letting the SP drift down and very few RNS . With JM , the company have acquired Yourgene , but , instead of building on that , he has just let the SP drift back to 44p .
I am eager to know more information from JM about .
1. R&D , and chances of new products on market .
2. Forward strategy to increase growth of company
3. Latest DHSC situation
4. Any boardroom changes
The fact is not even an RNS to inform the market that Dr Joanne Mason was the new R&D head to replace the previous one . We got to know through LinkedIn .
So, if we are likely to get a new CEO , after the DHSC case win , it would mean JM will be on his way. What about the fate of JW ? What does he bring to Novacyt ? What is exactly his remit ?
How much credibility does JM has now ? He , and David Allmond were the ones to talk about the £100M organic growth within 5 years from 2022. So can we trust him ?
We need to win this DHSC dispute , for the sake of the poor suffering investors who have been on Novacyt's journey from 2020. It's then we can see a new dynamic board room .